SomaLogic Announces Agreement with FDA to Identify Biomarkers for Therapeutic Biologics
By EsqSocial Corporation 02/11/20
Yesterday, SomaLogic, Inc. announced a new five-year agreement and collaboration with the FDA’s Division of Applied Regulatory Science to evaluate the utility of large-scale analysis of proteins for the identification of biomarkers that may be used to help demonstrate whether a proposed biosimilar is biosimilar to a reference product. According to SomaLogic, the project will use data generated on the SomaLogic SomaScan Platform to identify changes in circulating proteins in the blood following...
By: Goodwin